Sign in to get an email when it declares a dividend.
Astrazeneca plc dividend: key facts
Own Astrazeneca plc? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next AZN dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on London Stock Exchange in GBX. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
| Ex-dividend | Payment | Per share | Currency | Type |
|---|---|---|---|---|
| 6 Aug 2026 | Paid 8 Sep 2026 | $1.06 | USD | Interim |
| 19 Feb 2026 | Paid 23 Mar 2026 | $2.17 | USD | Final |
| 7 Aug 2025 | Paid 8 Sep 2025 | $1.03 | USD | Interim |
| 20 Feb 2025 | Paid 24 Mar 2025 | $2.10 | USD | Final |
| 8 Aug 2024 | Paid 9 Sep 2024 | $1.00 | USD | Interim |
| 22 Feb 2024 | Paid 25 Mar 2024 | $1.97 | USD | Final |
| 10 Aug 2023 | Paid 11 Sep 2023 | $0.93 | USD | Interim |
| 23 Feb 2023 | Paid 27 Mar 2023 | $1.97 | USD | Final |
| 11 Aug 2022 | Paid 12 Sep 2022 | $0.93 | USD | Interim |
| 24 Feb 2022 | Paid 28 Mar 2022 | $1.97 | USD | Interim |
| 12 Aug 2021 | Paid 13 Sep 2021 | $0.90 | USD | Interim |
| 25 Feb 2021 | Paid 29 Mar 2021 | $1.90 | USD | Interim |
| 13 Aug 2020 | Paid 14 Sep 2020 | $0.90 | USD | Interim |
| 27 Feb 2020 | Paid 30 Mar 2020 | $1.90 | USD | Interim |
| 8 Aug 2019 | Paid 9 Sep 2019 | $0.90 | USD | Interim |
| 28 Feb 2019 | Paid 27 Mar 2019 | $1.90 | USD | Final |
| 9 Aug 2018 | Paid 10 Sep 2018 | $0.90 | USD | Interim |
| 15 Feb 2018 | Paid 19 Mar 2018 | $1.90 | USD | Final |
| 10 Aug 2017 | Paid 11 Sep 2017 | $0.90 | USD | Interim |
| 16 Feb 2017 | Paid 20 Mar 2017 | $1.90 | USD | Final |
| 11 Aug 2016 | Paid 12 Sep 2016 | $0.90 | USD | Interim |
| 18 Feb 2016 | Paid 21 Mar 2016 | $1.90 | USD | Final |
| 13 Aug 2015 | Paid 14 Sep 2015 | $0.90 | USD | Interim |
| 19 Feb 2015 | Paid 23 Mar 2015 | $1.90 | USD | Final |
Five-year outlook
Estimates, not forecasts of what will be paid: dividends can be cut at any time.
| Period | Per share | Currency | Confidence |
|---|---|---|---|
| Next 12 months | $3.3082 | USD | High |
| Year 2 | $3.3549 | USD | Medium |
| Year 3 | $3.4023 | USD | Medium |
| Year 4 | $3.4503 | USD | Low |
| Year 5 | $3.4990 | USD | Low |
How we got these figures. Uneven record; a cautious 1.4% a year (half its average growth).
With no growth at all, each year would be $3.2932.
Reported financials
Annual figures from filings, converted to units.
| Year to | Revenue | Net income | EPS | Free cash flow | Source |
|---|---|---|---|---|---|
| 31 Dec 2025IFRS GBX | £0.59bn | £0.10bn | 6.54p | £0.12bnDerived | Source (opens in a new tab) |
| 31 Dec 2024IFRS GBX | £0.54bn | £0.07bn | 4.50p | £0.10bnDerived | Source (opens in a new tab) |
About Astrazeneca plc
AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions.
From Wikipedia, CC BY-SA 4.0.
Next 12 months
| 19 Feb 2027Ex-dividend | USD | $2.2332Estimate |
| 6 Aug 2027Ex-dividend | USD | $1.0750Estimate |
Estimate confidence: High
Financial health
A summary of the scores below, each 0 to 100. Based on the year to 31 Dec 2025.
Company news
- Baxfendy recommended for approval in the EU16 Nov 2026 · FCA National Storage Mechanism
- Imfinzi + EV approved in US in bladder cancer16 Nov 2026 · FCA National Storage Mechanism
- Klygefa (gefurulimab) approved in the US16 Nov 2026 · FCA National Storage Mechanism
- Klygefa (gefurulimab) approved in the EU16 Nov 2026 · FCA National Storage Mechanism
Dividend data and price last updated 18 Nov 2026.